Lois Swain, APRN
Family · Leesville, LANPI 1992211676
Payments from drug & device makers
Across 23 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$135
- Indivior Inc.$123
- Axsome Therapeutics, Inc.$94
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$50
- Alkermes, Inc.$44
- Otsuka America Pharmaceutical, Inc.$23
- plus $41 from 2 others
What the payments were for
- Food & beverage$510100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $135 |
| Indivior Inc. | 5 | $123 |
| Axsome Therapeutics, Inc. | 5 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $50 |
| Alkermes, Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Gilead | 1 | $23 |
| Abbott | 1 | $18 |
How this compares
$510 in reported general payments places this provider in the 45th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 121 | $75,270 |
| OzempicSemaglutide | 54 | $48,364 |
| JanuviaSitagliptin Phosphate | 15 | $13,642 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 65 | $12,741 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $10,586 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,334 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,467 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,531 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $3,861 |
| LantusInsulin Glargine,hum.Rec.Anlog | 15 | $3,405 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,582 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,816 |
| Ventolin HfaAlbuterol Sulfate | 18 | $970 |
| Atorvastatin Calcium | 213 | $929 |
| FenofibrateFenofibrate Nanocrystallized | 62 | $790 |
Paid to pharmacies, not to this prescriber.
Other family in Leesville
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.